HRT Financial’s Kalaris Therapeutics KLRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$73K Buy
25,560
+11,837
+86% +$45.8K ﹤0.01% 4229
2026
Q2
$55K Buy
13,723
+2,106
+18% +$10.9K ﹤0.01% 3749
2026
Q1
$67K Buy
+11,617
New +$103K ﹤0.01% 3415
2025
Q1
– Sell
-1,373
Closed -$13K – 3592
2024
Q4
$13K Buy
+1,373
New +$20.8K ﹤0.01% 2257
2023
Q1
– Sell
-2,088
Closed -$246K – 3326
2022
Q4
$246K Buy
+2,088
New +$354K ﹤0.01% 1842
2022
Q3
– Sell
-1,893
Closed -$169K – 3634
2022
Q2
$169K Buy
1,893
+1,291
+214% +$135K ﹤0.01% 2298
2022
Q1
$93K Buy
+602
New +$120K ﹤0.01% 2676
2021
Q3
– Sell
-3,486
Closed -$1.58M – 3862
2021
Q2
$1.58M Buy
+3,486
New +$1.8M 0.01% 744

Other funds holding KLRS

HRT Financial's KLRS Position: Q3 2026 in Review

HRT Financial increased its Kalaris Therapeutics (KLRS) stake by 86% in Q3 2026, buying an estimated $45.8K and bringing the position to 25,560 shares worth $73K. The position accounts for ﹤0.01% of the portfolio, ranked #4229.

HRT Financial first reported a position in KLRS in Q2 2021 and has held it in 8 quarters since. The position peaked at $1.58M in Q2 2021. 54 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.

  • HRT Financial held 25,560 shares of Kalaris Therapeutics worth $73K as of Q3 2026.
  • HRT Financial bought 11,837 Kalaris Therapeutics shares in Q3 2026, an estimated $45.8K.
  • Kalaris Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q3 2026, its #4229 holding.
  • HRT Financial first reported a position in Kalaris Therapeutics in Q2 2021 and has held it in 8 quarters since.
  • HRT Financial's Kalaris Therapeutics position peaked at $1.58M in Q2 2021.
  • 54 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.

Based on HRT Financial's 13F filing for Q3 2026, filed 13 Nov 2026.